New COVID-19 vaccine may be granted marketing authorisation shortly

Portfolio
The human medicines committee (CHMP) of the European Medicines Agency (EMA) has started a rolling review of VLA2001, a COVID-19 vaccine being developed by Valneva, the EU Amsterdam-based medicines watchdog has announced on Thursday.
koronavírus vakcina oltás oltakozás oltatás

EMA’s human medicines committee (CHMP) has announced today that it started a rolling review of VLA2001, a COVID-19 vaccine being developed by Valneva. 

The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults.

These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.

EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorisation application.

The Agency will assess the compliance of VLA2001 with the usual EU standards for effectiveness, safety and quality. While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review.

EMA will communicate further when the marketing authorisation application for the vaccine has been submitted.

On 10 November, the European Commission approved the eighth contract with a pharmaceutical company with a view to purchasing its potential vaccine against COVID-19. The contract with Valneva provides for the possibility for all EU Member States to purchase almost 27 million doses in 2022.

THE AGREEMENT ALSO INCLUDES THE POSSIBILITY TO ADAPT THE VACCINE TO NEW VARIANT STRAINS,

and for Member States to make a further order of up to 33 million additional vaccines in 2023.

The contract with Valneva comes in addition to an already secured broad portfolio of vaccines to be produced in Europe, including the contracts already signed with

Valneva is a European biotechnology company developing an inactivated virus vaccine, made of the live virus through chemical inactivation.

This is a traditional vaccine technology, used for 60-70 years, with established methods and high level of safety. Most of the flu vaccines and many childhood vaccines use this technology.

THIS IS CURRENTLY THE ONLY INACTIVATED VACCINE CANDIDATE IN CLINICAL TRIALS AGAINST COVID-19 IN EUROPE.

 

More in Economy

February 14, 2025 09:55

Petrol prices to be slightly trimmed off the top on Saturday

Diesel prices stay the same

Orbán Viktor a Kossuth rádió studiójában.
February 14, 2025 09:15

If Russia is reintegrated into the world economy, it is a huge opportunity for Hungary - Orbán

Hungarian Prime Minister sees a number of economic challenges too

építkezés daru építőipar ingatlanpiac
February 14, 2025 08:58

Hungary's construction sector might have weathered its rock bottom

Prospect still not bright, but there are small glimmers of hope

February 13, 2025 17:53

Hungary to build new oil pipeline with Serbia

A 180-kilometre pipeline

doktor orvos háziorvos rendel
February 13, 2025 16:19

Respiratory season may have peaked in Hungary

More than half of cases still due to influenza

feldolgozóipar, ipari termelés, ipar, gyártás
February 13, 2025 15:01

EU industry in decline, Hungary one of the worst hit member states

Severe crisis in the EU and in Hungary

LATEST NEWS

Detailed search